Intensity Therapeutics reports $7.1 million cash as of September 30, 2025 and extends cash runway to end of first quarter 2027

Reuters11-07

Intensity <a href="https://laohu8.com/S/LENZ">Therapeutics</a> reports $7.1 million cash as of September 30, 2025 and extends cash runway to end of first quarter 2027

Intensity Therapeutics Inc. reported cash and cash equivalents of $7.1 million as of September 30, 2025, with an additional $6.1 million raised in the fourth quarter of 2025, extending the company's cash runway until the end of the first quarter of 2027. Research and development expenses for the third quarter of 2025 were $1.6 million, down from $2.2 million in the same period of 2024, mainly due to reduced clinical trial costs following a pause in the INVINCIBLE-3 Study. The company plans to reinitiate patient enrollment in the INVINCIBLE-4 Study in the first quarter of 2026 after a protocol amendment. No sales or revenue figures were disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intensity Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE16758) on November 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581501733?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581501733","market":"nz","top_or_hot":-1,"title":"Intensity Therapeutics reports $7.1 million cash as of September 30, 2025 and extends cash runway to end of first quarter 2027","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Intensity <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> reports $7.1 million cash as of September 30, 2025 and extends cash runway to end of first quarter 2027\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Intensity Therapeutics Inc. reported cash and cash equivalents of $7.1 million as of September 30, 2025, with an additional $6.1 million raised in the fourth quarter of 2025, extending the company's cash runway until the end of the first quarter of 2027. Research and development expenses for the third quarter of 2025 were $1.6 million, down from $2.2 million in the same period of 2024, mainly due to reduced clinical trial costs following a pause in the INVINCIBLE-3 Study. The company plans to reinitiate patient enrollment in the INVINCIBLE-4 Study in the first quarter of 2026 after a protocol amendment. No sales or revenue figures were disclosed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intensity Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE16758) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intensity Therapeutics reports $7.1 million cash as of September 30, 2025 and extends cash runway to end of first quarter 2027</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntensity Therapeutics reports $7.1 million cash as of September 30, 2025 and extends cash runway to end of first quarter 2027\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 05:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Intensity <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> reports $7.1 million cash as of September 30, 2025 and extends cash runway to end of first quarter 2027\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Intensity Therapeutics Inc. reported cash and cash equivalents of $7.1 million as of September 30, 2025, with an additional $6.1 million raised in the fourth quarter of 2025, extending the company's cash runway until the end of the first quarter of 2027. Research and development expenses for the third quarter of 2025 were $1.6 million, down from $2.2 million in the same period of 2024, mainly due to reduced clinical trial costs following a pause in the INVINCIBLE-3 Study. The company plans to reinitiate patient enrollment in the INVINCIBLE-4 Study in the first quarter of 2026 after a protocol amendment. No sales or revenue figures were disclosed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intensity Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE16758) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INTS","symbol_name":"Intensity Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL3VdtJV:1","article_id":"2581501733","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581501733","pubTimestamp":1762463035,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Intensity Therapeutics reports $7.1 million cash as of September 30, 2025 and extends cash runway to end of first quarter 2027. Intensity Therapeutics Inc. reported cash and cash equivalents of $7.1 million as of September 30, 2025, with an additional $6.1 million raised in the fourth quarter of 2025, extending the company's cash runway until the end of the first quarter of 2027. Research and development expenses for the third quarter of 2025 were $1.6 million, down from $2.2 million in the same period of 2024, mainly due to reduced clinical trial costs following a pause in the INVINCIBLE-3 Study. The company plans to reinitiate patient enrollment in the INVINCIBLE-4 Study in the first quarter of 2026 after a protocol amendment. No sales or revenue figures were disclosed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational pu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INTS":"Intensity Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Intensity Therapeutics报告截至2025年9月30日现金为710万美元，并将现金跑道延长至2027年第一季度末","themeId":"7026f4aef5369e29e112f6f82189519d","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INTS":0.9},"content_text":"Intensity Therapeutics reports $7.1 million cash as of September 30, 2025 and extends cash runway to end of first quarter 2027\n    \n\n        Intensity Therapeutics Inc. reported cash and cash equivalents of $7.1 million as of September 30, 2025, with an additional $6.1 million raised in the fourth quarter of 2025, extending the company's cash runway until the end of the first quarter of 2027. Research and development expenses for the third quarter of 2025 were $1.6 million, down from $2.2 million in the same period of 2024, mainly due to reduced clinical trial costs following a pause in the INVINCIBLE-3 Study. The company plans to reinitiate patient enrollment in the INVINCIBLE-4 Study in the first quarter of 2026 after a protocol amendment. No sales or revenue figures were disclosed.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intensity Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE16758) on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581501733","isCrawlerRequest":true}